PREVENTION OF COMPLICATIONS IN COVID-PATIENTS TAKING INTO ACCOUNT THE KEY ISSUES OF POLYPHARMACY, RATIONAL PHARMACOTHERAPY
DOI:
https://doi.org/10.52340/jecm.2022.07.45Ключевые слова:
covid-19, complications, prevention, polypharmacy, pharmacotherapyАннотация
The pathogenesis of SARS-Cov-2 infection is based on massive immune dysregulation and tissue hypoxia, and the important determining factors of the severity of the course of the covid infection are concomitant diseases, therefore, timely detection of high-risk patients and their appropriate, rational pharmacotherapy is important. In the conditions of polypharmacy, the probability of pharmacokinetic and pharmacodynamic interaction is even higher in covid patients and has a negative impact on the outcome of the disease. Based on the above, it was interesting to determine the correlation between the cases of polypharmacy and the clinical outcome (hospitalization length and mortality rate) of hospitalized comorbid patients infected with SARS-CoV-2. A retrospective study was conducted on the basis of archival data of the First University Clinic. 300 hospitalized patients infected with SARS-CoV-2 (from September 2020 to December 2021) were randomly selected. Of the 300 selected patients, 197 were prescribed 5 or more drugs (polypharmacy). Polypharmacy, the excessive combined use of certain medications, was associated with a higher rate of adverse clinical outcomes in COVID-19 patients, especially in older, comorbid covid-patients, according to the results of the study.
Скачивания
Библиографические ссылки
McQueenie R, Foster HME, Jani BD, Katikireddi SV, Sattar N, Pell JP, Ho FK, Niedzwiedz CL, Hastie CE, Anderson J, et al. Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort. PLoS ONE. 2020;15(8): e0238091.
loanusi S, Mgbere O, Essien EJ. Polypharmacy among COVID-19 patients: a systematic review. J Am Pharm Assoc JAPhA. 2021;61(5):e14–25.
Potempski F, Bilimoria K: Polypharmacy in the age of COVID-19: medication management during a pandemic. University of Toronto Medical Journal 2021, 98(1):73-5.
Gutierrez-Valencia M, Izquierdo M, Cesari M, Casas-Herrero A, Inzitari M, Martinez-Velilla N. The relationship between frailty and polypharmacy in older people: a systematic review. Br J Clin Pharmacol. 2018;84(7):1432–44.
Pazan F, Wehling M. Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences. Eur Geriatr Med. 2021;12(3):443–52.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical research ed) 2021, 372.
Crescioli G, Brilli V, Lanzi C, Burgalassi A, Ieri A, Bonaiuti R, Romano E, Innocenti R, Mannaioni G, Vannacci A, et al. Adverse drug reactions in SARS-CoV-2 hospitalised patients: a case-series with a focus on drug-drug interactions. Intern Emerg Med. 2021;16(3):697–710.
Cantudo-Cuenca MD, Gutierrez-Pizarraya A, Pinilla-Fernandez A, Contreras-Macias E, Fernandez-Fuertes M, Lao-Dominguez FA, Rincon P, Pineda JA, Macias J, Morillo-Verdugo R. Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain. Sci Rep. 2021;11(1):12414.
Ailabouni NJ, Hilmer SN, Kalisch L, Braund R, Reeve E. COVID-19 pandemic: considerations for safe medication use in older adults with multimorbidity and polypharmacy. In., vol. 76: Oxford University Press US; 2021: 1068–1073.
Surmelioglu N, Yalcin N, Kuscu F, Candevir A, Inal AS, Komur S, Kurtaran B, Demirkan K, Tasova Y. Physicians’ knowledge of potential COVID-19 drug-drug interactions: an online survey in turkey. Postgrad Med. 2021;133(2):237–41.
Загрузки
Опубликован
Как цитировать
Выпуск
Раздел
